Nasdaq: Vaxcyte Advances VAX-31 Infant Study to Stage 2 Following Positive Stage 1 Safety Data
Vaxcyte, Inc. announced that it has progressed to Stage 2 of its Phase 2 infant study for the VAX-31 pneumococcal conjugate vaccine after a review of Stage 1 safety and tolerability data. VAX-31 ...
Vaxcyte Advances VAX-31 Infant Study to Stage 2 Following Positive Stage 1 Safety Data
Welcome to VAX VacationAccess Join over 203,000 of your fellow travel advisors to earn, learn and grow in the premier leisure travel marketplace. Learn More Register Now
Welcome to VAX VacationAccess You’re joining a community of over 200,000 travel advisors who trust our award-winning booking platform as their one-stop shop for all things travel. Here, you’ll find an extensive collection of content and resources curated exclusively for travel advisors. Ready to see what VAX can do for you? Watch our quick virtual tour to explore the tools and features ...
Need help with a password reset? Want to learn more about VAX features? Find out these and more in our Help Center.
VAX Tech Support If you need assistance with your VAX credentials you will need to be prepared with some required information in order for the team to assist you. Please review the requirements prior to calling.
Registration Welcome to VAX VacationAccess® Before registering, please verify your agency does not already have access to VAX VacationAccess through a host agency or consortia. If your agency already has access, contact your VAX Site Manager to request login credentials.
Seeking Alpha: Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in ...
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
Nasdaq: Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class ...
Following Interactions with FDA on VAX-31 Adult Program, Including End-of-Phase 2 Meeting, Company Finalizing Phase 3 Clinical Program to Validate VAX-31 as Potential New Standard-of-Care Adult PCV; ...
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class ...